- Home
- SOTK vs PLX Comparison
SOTK vs PLX Comparison
Compare SOTK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOTK
- PLX
- Stock Information
- Founded
- SOTK 1975
- PLX 1993
- Country
- SOTK United States
- PLX United States
- Employees
- SOTK N/A
- PLX N/A
- Industry
- SOTK Industrial Machinery/Components
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOTK Technology
- PLX Health Care
- Exchange
- SOTK Nasdaq
- PLX Nasdaq
- Market Cap
- SOTK 58.5M
- PLX 122.6M
- IPO Year
- SOTK 1987
- PLX 1998
- Fundamental
- Price
- SOTK $3.77
- PLX $1.47
- Analyst Decision
- SOTK Hold
- PLX Strong Buy
- Analyst Count
- SOTK 1
- PLX 1
- Target Price
- SOTK N/A
- PLX $15.00
- AVG Volume (30 Days)
- SOTK 5.5K
- PLX 1.2M
- Earning Date
- SOTK 07-10-2025
- PLX 08-13-2025
- Dividend Yield
- SOTK N/A
- PLX N/A
- EPS Growth
- SOTK N/A
- PLX N/A
- EPS
- SOTK 0.08
- PLX 0.05
- Revenue
- SOTK $20,504,381.00
- PLX $59,764,000.00
- Revenue This Year
- SOTK N/A
- PLX $65.02
- Revenue Next Year
- SOTK $9.53
- PLX $57.34
- P/E Ratio
- SOTK $46.38
- PLX $30.63
- Revenue Growth
- SOTK 4.08
- PLX 0.18
- 52 Week Low
- SOTK $3.50
- PLX $0.82
- 52 Week High
- SOTK $6.05
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- SOTK 47.08
- PLX 42.57
- Support Level
- SOTK $3.63
- PLX $1.32
- Resistance Level
- SOTK $3.88
- PLX $1.67
- Average True Range (ATR)
- SOTK 0.10
- PLX 0.11
- MACD
- SOTK -0.00
- PLX 0.03
- Stochastic Oscillator
- SOTK 45.00
- PLX 41.86
About SOTK Sono-Tek Corporation
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.